keyword
MENU ▼
Read by QxMD icon Read
search

Angioedema

keyword
https://www.readbyqxmd.com/read/28734860/the-expanding-field-of-biologics-in-the-management-of-chronic-urticaria
#1
Shyam Joshi, David A Khan
Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab...
July 19, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28731410/infectious-and-noninfectious-pulmonary-complications-in-patients-with-primary-immunodeficiency-disorders
#2
REVIEW
R Yazdani, H Abolhassani, M Asgardoon, M Shaghaghi, M Modaresi, G Azizi, A Aghamohammadi
Primary immunodeficiency disorders (PIDs) are caused by 1 or more defects of the immune system. Patients are more likely to experience recurrent and/or severe infections and tend to develop a wide range of complications. Respiratory diseases are the main and initial manifestation in most cases and the most common complication. Pulmonary complications cause significant morbidity and mortality in patients with PIDs. Early diagnosis and appropriate treatment can prevent or at least slow the development of respiratory complications...
2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/28725969/mastocytosis-from-a-molecular-point-of-view
#3
REVIEW
Daniel Elieh Ali Komi, Todd Rambasek, Stefan Wöhrl
Mast cells (MCs) are physiologically activated by binding of stem cell factor (SCF) to the extracellular domains of the Kit receptor. This binding increases the proliferation and prolongs the survival of normal mature MCs, as well as intensifies the release of mediators. In mastocytosis, somatic mutations of the coding Kit gene cause autocrine dysregulation and lead to constitutive KIT activation even in the absence of its ligand SCF. Clinical symptoms are caused by MC-mediator release and/or infiltration of MCs into tissues...
July 19, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28722207/antihypertensive-drug-associated-angioedema-effect-modification-by-race-ethnicity
#4
Marsha E Reichman, Michael Wernecke, David J Graham, Jiemin Liao, John Yap, Yoganand Chillarige, Mary Ross Southworth, Stephine Keeton, Margie R Goulding, Katrina Mott, Jeffrey A Kelman
PURPOSE: Assess angioedema risk with exposure to angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) compared with beta-blockers, by race/ethnicity. METHODS: New-user cohorts of Medicare beneficiaries 65 years or older initiating ACEI, ARB, or beta-blocker treatment from March 2007 to March 2014 were constructed. Angioedema incidence rates by drug and race/ethnicity were computed for 1-30 and 31-365 days of treatment. Cox proportional hazards regression was used to examine angioedema risk between cohorts...
July 19, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28720639/angioedema-spotlight-a-closer-examination-of-sacubitril-valsartan-safety-results
#5
Ryan E Owens, Carrie S Oliphant
Incorporation of neprilysin inhibition into heart failure pharmacotherapy regimens has recently been recommended by U.S. guidelines, based on results from the PARADIGM-HF trial comparing sacubitril/valsartan to enalapril. While most of the discussion has focused on efficacy, a closer examination of the safety results, particularly the incidence of angioedema during the run-in and double-blind periods, is also warranted. Although no major safety concerns were identified, an angioedema risk comparable to enalapril was found, primarily in the black population...
July 2017: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/28720373/incidence-of-adverse-contrast-reaction-following-nonintravenous-urinary-tract-imaging
#6
Robert H Blackwell, Eric J Kirshenbaum, Matthew A C Zapf, Anai N Kothari, Paul C Kuo, Robert C Flanigan, Gopal N Gupta
Adverse reactions (ARs) to intravenous (IV) radiographic contrast range from mild urticaria to life-threatening anaphylaxis. Intraluminal contrast dye is routinely used in the urinary tract with a minimal perceived risk of AR. We used the Healthcare Cost and Utilization Project State Inpatient Databases for California and Florida from 2007 to 2011 to identify patients who received urinary tract contrast dye for retrograde pyelography, percutaneous pyelography, retrograde/other cystogram, and ileal conduitogram...
February 2017: European Urology Focus
https://www.readbyqxmd.com/read/28715060/the-complex-interaction-between-polycystic-ovary-syndrome-and-hereditary-angioedema-case-reports-and-review-of-the-literature
#7
Marina Iahn-Aun, Marcelo Vivolo Aun, Antonio Abílio Motta, Jorge Kalil, Pedro Giavina-Bianchi, Sylvia Asaka Hayashida, Edmund Chada Baracat, Gustavo Arantes Maciel
Importance: Hereditary angioedema (HAE) is a rare but severe disease, with high risk of death, and attacks have been associated to high estrogen levels. Polycystic ovary syndrome (PCOS) is a common hyperandrogenic condition, which is frequently treated with combined oral contraceptives. Objective: The aim of this study was to describe 2 clinical cases of young women diagnosed as having PCOS who developed HAE attacks after the introduction of combined estrogen-progestin pills to treat PCOS symptoms...
July 2017: Obstetrical & Gynecological Survey
https://www.readbyqxmd.com/read/28692169/the-relationship-between-anxiety-and-quality-of-life-in-children-with-hereditary-angioedema
#8
Aharon Kessel, Henriette Farkas, Shmuel Kivity, Nóra Veszeli, Kinga Viktória Kőhalmi, Batya Engel-Yeger
BACKGROUND: The severe life-threatening characteristics of hereditary angioedema (HAE) with C1-inhibitor deficiency (C1-INH-HAE) can affect anxiety levels among pediatric patients. This emotional burden together with the physical restrictions of C1-INH-HAE may decrease children's health-related quality of life (HRQoL). OBJECTIVE: (1) To compare anxiety state and trait between children with C1-INH-HAE and healthy controls (2) To examine the relationship between the level of anxiety of children with C1-INH-HAE, their disease activity/affected sites and their HRQoL (3) To predict the HRQoL of children with C1-INH-HAE based on their anxiety level and disease activity/affected sites...
July 10, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28690728/-drug-induced-angioedema-a-rare-side-effect-of-simvastatin
#9
Abdelilah Ben El Mekki, Ali Chaib
No abstract text is available yet for this article.
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28690642/breakthrough-attacks-in-patients-with-hereditary-angioedema-receiving-long-term-prophylaxis-are-responsive-to-icatibant-findings-from-the-icatibant-outcome-survey
#10
Werner Aberer, Marcus Maurer, Laurence Bouillet, Andrea Zanichelli, Teresa Caballero, Hilary J Longhurst, Amandine Perrin, Irmgard Andresen
BACKGROUND: Patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) experience recurrent attacks of cutaneous or submucosal edema that may be frequent and severe; prophylactic treatments can be prescribed to prevent attacks. However, despite the use of long-term prophylaxis (LTP), breakthrough attacks are known to occur. We used data from the Icatibant Outcome Survey (IOS) to evaluate the characteristics of breakthrough attacks and the effectiveness of icatibant as a treatment option...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28687115/angioedema-challenges-and-insights
#11
EDITORIAL
Marc A Riedl
No abstract text is available yet for this article.
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687114/angioedema-an-orphan-symptom-with-its-own-orphan-disease
#12
EDITORIAL
Stephen A Tilles
No abstract text is available yet for this article.
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687113/pharmacoeconomics-of-orphan-disease-treatment-with-a-focus-on-hereditary-angioedema
#13
REVIEW
William R Lumry
This article discusses orphan diseases, their prevalence, legislative incentives to encourage development of therapies, and the impact of treatment on health care payment systems. Specifically, the cost burden of hereditary angioedema on patients, health care systems, and society is reviewed. The impact of availability of and access to novel and specific therapies on morbidity, mortality, and overall burden of disease is explored. Changes in treatment paradigms to improve effect and reduce cost of treatment are presented...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687112/burden-of-illness-and-quality-of-life-measures-in-angioedema-conditions
#14
REVIEW
Teresa Caballero, Nieves Prior
Burden of illness studies and evaluation of health-related quality of life using validated questionnaires have become an important task in the comprehensive management of angioedema conditions, mainly angioedema associated with chronic spontaneous urticaria and hereditary angioedema caused by C1-inhibitor deficiency. A review of the principal tools and studies is presented. Both diseases present a higher proportion of psychiatric disorders, impair work and studies productivity, and produce high direct and indirect costs...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687111/emerging-therapies-in-hereditary-angioedema
#15
REVIEW
Meng Chen, Marc A Riedl
Remarkable progress has been made in the treatment of bradykinin-mediated angioedema with the advent of multiple new therapies. Patients now have effective medications available for prophylaxis and treatment of acute attacks. However, hereditary angioedema is a burdensome disease that can lead to debilitating and dangerous angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687110/hereditary-angioedema-with-normal-c1-inhibitor-update-on-evaluation-and-treatment
#16
REVIEW
Markus Magerl, Anastasios E Germenis, Coen Maas, Marcus Maurer
A new form of hereditary angioedema (HAE) was identified in the year 2000. Its clinical appearance resembles HAE types I and II, which are caused by mutations that result in a deficiency of C1 inhibitor (C1-INH). In patients with the new form of HAE, C1-INH plasma levels and function values are normal, so it's termed HAE with normal C1-INH (HAE-nC1). HAE-nC1, in a subgroup of patients, is thought to be caused by mutations that affect the F12 gene. The diagnosis of HAE-nC1 is based on history and clinical criteria...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687109/prophylactic-therapy-for-hereditary-angioedema
#17
REVIEW
Hilary Longhurst, Emily Zinser
Long-term prophylaxis is needed in many patients with hereditary angioedema and poses many challenges. Attenuated androgens are effective in many but are limited by side effect profiles. There is less evidence for efficacy of tranexamic acid and progestagens; however, the small side effect profile makes tranexamic acid an option for prophylaxis in children and progestagens an option for women. C1 inhibitor is beneficial, but at present requires intravenous delivery and may need dose titration for maximum efficacy...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687108/acute-management-of-hereditary-angioedema-attacks
#18
REVIEW
Constance H Katelaris
Several treatment modalities have become available for management of acute hereditary angioedema (HAE) attacks in the last 15 years. Most are now available to patients in North America, Europe, United Kingdom, and Australia, but few options exist in developing countries. Preferred contemporary use of the treatments to be discussed is "on demand," because control remains with the patient and delays in treatment access avoided. Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687107/laboratory-approaches-for-assessing-contact-system-activation
#19
REVIEW
Sandra C Christiansen, Bruce L Zuraw
Hereditary angioedema (HAE) is a rare autosomal dominant disease clinically characterized by recurrent, often unpredictable attacks of subcutaneous and mucosal swelling. Acute episodes are debilitating, painful, disfiguring, and potentially fatal. HAE type I and type II result from a deficiency in the plasma level of functional C1 inhibitor. HAE with normal levels of C1 inhibitor has been recognized. There is evidence that contact activation underlies the recurrent attacks of swelling. This article reviews laboratory parameters to detect contact system activation and implications for diagnosis of HAE and other forms of bradykinin-mediated angioedema...
August 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28687106/pathogenesis-of-hereditary-angioedema-the-role-of-the-bradykinin-forming-cascade
#20
REVIEW
Allen P Kaplan, Kusumam Joseph
Hereditary angioedema (HAE) is an autosomal-dominant disorder owing to mutations in the C1 inhibitor gene. Type I is characterized by a low C1 inhibitor protein level and diminished functional activity, whereas type II has a normal (or elevated) protein level but diminished function. When functional levels drop beyond 40% of normal, attacks of swelling are likely to occur due to overproduction of bradykinin. Angioedema can be peripheral, abdominal, or laryngeal. The typical duration of episodes is 3 days. Therapies include C1 inhibitor replacement for prophylaxis or acute therapy, whereas inhibition of kallikrein or blockade at the bradykinin receptor level can interrupt acute episodes of swelling...
August 2017: Immunology and Allergy Clinics of North America
keyword
keyword
4259
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"